



US008927592B2

(12) **United States Patent**
Gupta

(10) **Patent No.:** **US 8,927,592 B2**
(45) **Date of Patent:** **Jan. 6, 2015**

- (54) **ANTITUMORAL USE OF CABAZITAXEL**
- (75) Inventor: **Sunil Gupta**, Chester Springs, PA (US)
- (73) Assignee: **Aventis Pharma SA**, Antony (FR)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

2008/0279923	A1	11/2008	Bradke et al.
2010/0311825	A1	12/2010	Rortais et al.
2011/0105598	A1	5/2011	Gurjar et al.
2011/0144362	A1	6/2011	Billot et al.
2011/0160159	A1	6/2011	Ryan
2011/0177970	A1	7/2011	Chauchereau et al.
2011/0237540	A1	9/2011	Crawford et al.
2012/0077845	A1	3/2012	Dalton et al.
2012/0115806	A1	5/2012	Magherini

FOREIGN PATENT DOCUMENTS

EP	0817779	1/2000
EP	2177630	4/2010
FR	2732340	10/1996
WO	WO 94/18164	8/1994
WO	WO 96/30355	10/1996
WO	WO 96/30356	10/1996
WO	WO 00/10547	3/2000
WO	WO 2005/028462	3/2005
WO	WO 2006/062811	6/2006
WO	WO 2010/117668	10/2010
WO	WO 2010/128258	11/2010
WO	WO 2011/051894	5/2011
WO	WO 2011/063421	5/2011
WO	WO 2011/124669	10/2011
WO	WO 2011/130317	10/2011
WO	WO 2011/130566	10/2011

- (21) Appl. No.: **13/456,720**
- (22) Filed: **Apr. 26, 2012**

- (65) **Prior Publication Data**
US 2012/0301425 A1 Nov. 29, 2012

Related U.S. Application Data

- (63) Continuation of application No. PCT/IB2010/054866, filed on Oct. 27, 2010.
- (60) Provisional application No. 61/389,969, filed on Oct. 5, 2010, provisional application No. 61/383,933, filed on Sep. 17, 2010, provisional application No. 61/369,929, filed on Aug. 2, 2010, provisional application No. 61/355,888, filed on Jun. 17, 2010, provisional application No. 61/355,834, filed on Jun. 17, 2010, provisional application No. 61/293,903, filed on Jan. 11, 2010, provisional application No. 61/256,160, filed on Oct. 29, 2009.

- (51) **Int. Cl.**
A61K 31/337 (2006.01)
A61K 31/573 (2006.01)
A61K 31/164 (2006.01)
A61K 31/56 (2006.01)
A61K 45/06 (2006.01)

- (52) **U.S. Cl.**
CPC *A61K 31/337* (2013.01); *A61K 31/164* (2013.01); *A61K 31/56* (2013.01); *A61K 31/573* (2013.01); *A61K 45/06* (2013.01)
USPC **514/449**

- (58) **Field of Classification Search**
CPC A61K 31/337; A61K 31/573
See application file for complete search history.

- (56) **References Cited**
U.S. PATENT DOCUMENTS

5,438,072	A	8/1995	Bobee et al.
5,847,170	A	12/1998	Bouchard et al.
5,889,043	A	3/1999	Bouchard et al.
5,962,705	A	10/1999	Didier et al.
6,160,135	A	12/2000	Bouchard et al.
6,331,635	B1	12/2001	Bouchard et al.
6,346,543	B1	2/2002	Bissery et al.
6,372,780	B2	4/2002	Bouchard et al.
6,387,946	B1	5/2002	Bouchard et al.
6,403,634	B1	6/2002	Bissery
7,241,907	B2	7/2007	Didier et al.
7,772,274	B1	8/2010	Palepu
2002/0038038	A1	3/2002	Bouchard et al.
2004/0126379	A1	7/2004	Adolf et al.

OTHER PUBLICATIONS


Mita et al. *Clinical Cancer Research*, 2009, vol. 15, pp. 723-730.*
Tannock et al. *N. Engl. J. Med.*, 2004, vol. 351, pp. 1502-1512.*
Beardsley et al. *Current Opinions in Supportive and Palliative Care*, Sep. 2008, vol. 2, pp. 161-166.*

(Continued)

Primary Examiner — James D Anderson
(74) *Attorney, Agent, or Firm* — Kelly L. Bender

(57) **ABSTRACT**

The invention relates to a compound of formula:



which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

(56)

References Cited

OTHER PUBLICATIONS

- Parkin, et al., Global Cancer Statistics, (2002), *CA Cancer J. Clin.*, (2005), vol. 55, pp. 74-108.
- Hellerstedt, et al., The Current State of Hormonal Therapy for Prostate Cancer, *CA Cancer J. Clin.*, (2002), vol. 52, pp. 154-179.
- Horwitz et al., External Beam Radiation Therapy for Prostate Cancer, *CA Cancer J. Clin.*, (2000); vol. 50, pp. 349-375.
- Pienta et al., Advances in Prostate Cancer Chemotherapy: A New Era Begins, *CA Cancer J. Clin.*, (2005), vol. 55, pp. 300-318.
- Cabral, Factors Determining Cellular Mechanisms of Resistance to Antimitotic Drugs, *Drug Resistance Updates*, (2001), vol. 4 No. 1, pp. 3-8.
- Dumontet, et al., Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport and Cell Death, *J. Clin. Oncol.*, (1999), vol. 17, No. 3, pp. 1061-1070.
- Haleblian, et al., Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications, *J. Pharm. Sci.*, (1975), pp. 1269-1288.
- Melzack, The McGill Pain Questionnaire: Major Properties and Scoring Methods; *Pain*, vol. 1, (1975), pp. 277-299.
- Berry, et al., Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone, *Journal of Clinical Oncology*, (2006), vol. 24, No. 18, pp. 2828-2835.
- Fizaz, et al., New agents in Metastatic Prostate Cancer, *Eur. J. Cancer*, 2009, vol. 45, Supp. 1., pp. 379-380.
- http://clinicaltrials.gov/archive/NCT00417079/2006_12_28, View of NCT00417079 on Dec. 28, 2006—XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC). Retrieved on Feb. 8, 2012.
- de Bono, et al., Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel Treatment: a Randomized Open-Label Trial, *Lancet*, vol. 376, No. 9747, (2010), pp. 1147-1154.
- Galsky, et al., Cabazitaxel, *Nature Reviews—Drug Discovery*, vol. 9, (2010), pp. 677-678.
- International Search Report for WO2011/051894 dated May 5, 2011.
- Jevtana Prescribing Information, pp. 1-25, Jun. 17, 2010.
- Antonarakis & Eisenberger, Phase III Trials with Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer. Time to Learn From Past Experiences, 31(14) *J. Clin. Oncol.*, 1709-12 (2013).
- Armstrong & George, New Drug Development in Metastatic Prostate Cancer, *Urologic Oncol. Seminars & Orig. Invest.*, 430-437 (2008).
- Beer et al., Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel compared with Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report from the ASCENT Investigators, 25(6) *J. Clin. Oncol.*, 669-674 (2007).
- Berry et al., Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients with Asymptomatic Hormone Refractory Prostate Cancer, 168(6) *J. Urol.*, 2439-43 (2002).
- Booth et al., From the Analyst's Couch: *Oncology Trials 2 Nature Reviews Drug Discovery*, 609-610 (Aug. 2003).
- Cabral, Factors Determining Cellular Mechanisms of Resistance to Antimitotic Drugs, 4 *Drug Resistance Updates*, 3-8 (2001).
- Carducci et al., A Phase 3 Randomized Controlled Trial of the Efficacy and Safety of Abiraterone in Men with Metastatic Hormone-Refractory Prostate Cancer, 110(9) *Cancer*, 1959-66 (2007).
- D'Amico, US Food and Drug Administration Approval of Drugs for the Treatment of Prostate Cancer: A New Era Has Begun, *J. Clin. Oncol.*, 32(4) 362-364 (2014).
- Di Lorenzo et al., Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study, 54(5) *Europ. Urol.*, 1089-1096 (2008).
- Diéras et al., Larotaxel in Combination with Trastuzumab in Patients with HER2+ Metastatic Breast Cancer: Interim Analysis of an Open
- Diéras et al., Phase II Multicenter Study of Larotaxel (XRP9881), a Novel Taxoid, in Patients with Metastatic Breast Cancer Who Previously Received Taxane-Based Therapy, 19 *Annals of Oncol.*, 1255-1260 (2008).
- Dumontet & Sikic, Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death, 17(3) *J. Clin. Oncol.*, 1061-1070 (1999).
- Halabi et al., Prostate-Specific Antigen Changes as Surrogate for Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Second Line Therapy, 31(31) *J. Clin. Oncol.*, 3944-50 (2013).
- Higano et al., Phase 1/2 Dose-Escalation Study of a GM-CSF-Secreting, Allogeneic, Cellular Immunotherapy for Metastatic Hormone-Refractory Prostate Cancer, 113(5) *Cancer*, 975-984 (Sep. 1, 2008).
- Kaur et al., Suramin's Development, What Did We Learn, 20 *Investigational New Drugs*, 209-219 (2002).
- Kola & Landis, Can the Pharmaceutical Industry Reduce Attrition Rate?, 3 *Nature Reviews Drug Discovery*, 711-15 (2004) (previously cited).
- Mackinnon et al., Molecular Biology Underlying the Clinical Heterogeneity of Prostate Cancer: An Update, 133 (7) *Arch. Pathol. Lab. Med.*, 1033-40 (Jul. 2009).
- Michaelson et al., Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer, 32(2) *J. Clin. Oncol.*, 76-82 (2014).
- Mulcahy, Phase 3 Trial of Immunotherapy for Metastatic Prostate Cancer Terminated, *Medscape Medical News* (Oct. 17, 2009), [retrieved on Jun. 26, 2014] from: <http://www.medscape.com/viewarticle/582220>.
- Ramiah et al., Clinical Endpoints for Drug Development in Prostate Cancer, 18 *Curr. Opin. Urol.*, 303-308 (2008).
- Slovin et al., Ipilimumab Alone or in Combination with Radiotherapy in Metastatic Castration-Resistant Prostate Cancer: Results from an Open-Label, Multicenter Phase I/II Study, 24 *Annals of Oncol.*, 1813-1828 (2013).
- Small et al., Randomized Phase II Study Comparing 4 Monthly Doses of Ipilimumab (MDX-010) as a Single Agent or in Combination with a Single Dose of Docetaxel in Patients with Hormone-Refractory Prostate Cancer, 24(18S) *J. Clin. Oncol. (Meeting Abstracts)* S4609 (Jun. 2006).
- Small et al., Granulocyte Macrophage Colony Stimulating Factor-Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer, 13 *Clin. Cancer Res.*, 3883-3891 (2007).
- Sternberg et al., Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial, 85 *Oncol.*, 208-215 (2013).
- Susman, ASCO: Calcitriol Fails in ASCENT-2 Prostate CA Trial, *MedPage Today* (Jun. 9, 2010), [retrieved on Jun. 27, 2014] from: <http://www.medpagetoday.com/MeetingCoverage/ASCO/20575>.
- Van Cutsem et al., A Phase III Study Comparing Larotaxel to 5-FU (Continuous Intravenous 5-FU or Capecitabine) in Patients with Advanced Pancreatic Cancer (APC) Previously Treated with a Gemcitabine Containing Regimen, 21 (6S) *Annals of Oncol. Oral Presentations*, O-0007 (Jul. 2010).
- Van Hook et al., Orteronel for the Treatment of Prostate Cancer, 10(5) *Future Oncol.*, 803-811 (2014).
- Wiehce & Hanson, The Effect of Genetic Variability on Drug response in Conventional Breast Cancer Treatment, 625 *Eur. J. Pharmacol.*, 122-130 (2009).
- Williams, Discontinued Drugs in 2008: *Oncology Drugs*, 18(11) *Expert. Opin. Investig. Drugs* 1581-1594 (2009).
- Wirth & Froschermaier, The Antiandrogen Withdrawal Syndrome, 25 (Suppl. 2) *Urol Res.*, S67-71 (1997).
- Zafrouk et al., Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-Small Cell Lung Cancer, 3 *J. Thorac. Oncol.* 894-901 (2008).
- Zielinski & Chi, Custirsen (OGX-011): A Second-Generation

(56)

References Cited

OTHER PUBLICATIONS

- Novacea, Inc. SEC Form 8-K at 1.02, (2008) [retrieved on Jun. 27, 2014] from: <http://www.sec.gov/Archives/edgar/data/1178711/000119312508077953/d8k.htm>.
- Sanofi-Aventis SEC Form 20-F (Dec. 31, 2006) at 39, [retrieved on Jun. 27, 2014] from: <http://www.sec.gov/Archives/edgar/data/1121404/000119312507072848/d20f.htm>.
- Avastin (bevacizumab), Prescribing Information (Label) Jul. 2009.
- Yervoy (ipilimumab), Prescribing Information (Label), Dec. 2013.
- A Randomized, Open-Label, Phase 3 Study of Larotaxel IV Every 3 Weeks Versus Capecitabine (Xeloda®) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients with Metastatic Breast Cancer (MBC) Progressing After Taxanes and Anthracycline Therapy (EFC6089) (2012), [retrieved on Jun. 27, 2014] from: http://en.sanofi.com/img/content/study/EFC6089_summary.pdf.
- Bristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy® (Ipilimumab) in Previously-Treated Castration Resistant Prostate Cancer, Press Release Sep. 12, 2013 [retrieved on Jun. 27, 2014] from: <http://news.bms.com/press-release/rd-news/bristol-myers-squibb-reports-results-phase-3-trial-yervoy/ipilimumab-previous>.
- ClinicalTrials.gov, Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated with one Cytotoxic Chemotherapy Regimen [retrieved on Jun. 27, 2014] from: <https://clinicaltrials.gov/ct2/show/NCT00069745?term=SPARC&cond=prostate&rank=3>.
- ClinicalTrials.gov, Larotaxel every 3 weeks vs. capecitabine in patients with metastatic breast cancer progressing after taxanes and anthracycline therapy [retrieved on Jun. 24, 2014] from: <https://clinicaltrials.gov/ct2/show/NCT00081796?term=larotaxel&rank=7>.
- ClinicalTrials.gov, Larotaxel plus cisplatin vs. gemcitabine plus cisplatin in first line treatment of patients with locally advanced/metastatic bladder cancer [retrieved on Jun. 24, 2014] from: <https://clinicaltrials.gov/ct2/show/NCT00625664?term=larotaxel&rank=4>.
- ClinicalTrials.gov, Larotaxel vs. 5-FU or capecitabine in patients with pancreatic cancer previously treated with gemcitabine [retrieved on Jun. 24, 2014] from: <https://clinicaltrials.gov/ct2/show/NCT00417209?term=larotaxel&rank=2>.
- Press Release: OncoGenex Announces Top-Line Survival results of Phase 3 Synergy Trial Evaluating Custirsen for Metastatic Castration-Resistant Prostate Cancer, PRNewswire Apr. 28, 2014.
- Press Release: Roche Provides Update on Phase III study of Avastin in Men with Late Stage Prostate Cancer, Media Release Mar. 12, 2010 [retrieved on Jun. 27, 2014] from: http://www.roche.com/media/media_releases/med-cor-2010-03-12.htm.
- Press Release: Takeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe, Jun. 19, 2014 [retrieved on Jun. 27, 2014] from: http://www.takeda.com/news/2014/20140619_6615.html.
- Jevtana NDA Clinical Overview, excerpt, (2014), pp 2-13.
- Cisternino, et al., Nonlinear Accumulation in the Brain of the New Taxoid TXD258 Following Saturation of P-Glycoprotein at the Blood-Brain Barrier in Mice and Rats, *British Journal of Pharmacology*, (2003), vol. 138, pp. 1367-1375.
- Pivot, et al., Multicenter Phase 2 Study of XRP6258 in Taxane-Resistant Metastatic Breast Cancer (MBC) Patients (pts). *Breast Cancer Research and Treatment*, (2005), vol. 94, No. Suppl. 1, p. S68, Abst. 1084.
- Attard, et al., Update on Tubulin-Binding Agents, *Pathologic Biologie*, vol. 54, (2006), pp. 72-84.
- Beardsley, et al., Systemic Therapy After First-Line Docetaxel in Metastatic Castration-Resistant Prostate Cancer, *Current Opinion in Supportive and Palliative Care*, (2008), vol. 2, No. 3, pp. 161-166.
- Pivot, et al., A Multicenter Phase II Study of XRP6258 Administered as a 1-h i.v. Infusion Every 3 Weeks in Taxane-Resistant Metastatic
- The National Horizon Scanning Centre of National Institute for Health Research, Cabazitaxel (XRP-6258) for Hormone Refractory, Metastatic Prostate Cancer—Second Line After Docetaxel, University of Birmingham, pp. 1-6, (2009).
- Sanofi-Aventis Press Release: 2006: In a Difficult Environment, Another Year of Growth in Adjusted EPS Excluding Selected Items, (Feb. 13, 2007), pp. 1-31.
- Buonerba, et al., Docetaxel Rechallenge in Castration-Resistant Prostate Cancer: Scientific Legitimacy of Common Clinical Practice, *European Urology*, (2010), vol. 58, No. 4, pp. 636-637.
- Di Lorenzo, et al., Castration-Resistant Prostate Cancer: Current and Emerging Treatment Strategies, *Drugs*, (2010), vol. 70, No. 8, pp. 983-1000.
- Yoo, et al., XRP6258—Induced Gene Expression Patterns in Head and Neck Cancer Carcinoma, *Laryngoscope*, (2010), vol. 120, No. 6, pp. 1114-1119.
- Shabafrouz, et al., New Drugs at the Horizon for Men With Prostate Cancer, *Revue Medicale Suisse*, (2010), vol. 6, No. 250, pp. 1057-1058 & 1060-1061.
- Dorff, Cabazitaxel in Prostate Cancer: Stretching a String, *Lancet*, (2010), vol. 376, No. 9747, pp. 1119-1120.
- Bouchet, et al., Cabazitaxel, a New Taxane With Favorable Properties, *Drugs of Today*, (2010), vol. 46, No. 10, pp. 735-742.
- Pal, et al., Critical Appraisal of Cabazitaxel in the Management of Advanced Prostate Cancer, *Clinical Interventions in Aging*, (2010), vol. 5, pp. 395-402.
- Sartor, et al., Improving Outcomes With Recent Advances in Chemotherapy for Castrate-Resistant Prostate Cancer, *Clinical Genitourinary Cancer*, (2010), vol. 8, No. 1, pp. 23-28.
- Pouessel, et al., Actualities in Prostate Cancer in ASCO Annual Meeting 2010, *Bulletin du Cancer*, (2010), vol. 97, No. 12, pp. 1563-1572.
- Richards, Improved Survival in Second-Line Advanced Prostate Cancer Treated With Cabazitaxel, *Nature Reviews Clinical Oncology*, (2010), vol. 7, No. 12, p. 671.
- De Bono, et al., Cabazitaxel or Mitoxantrone With Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel: Final Results of a Multinational Phase III Trial (TROPIC), 46th Annu Meet Am Soc Clin Oncol (ASCO), *J. Clin. Oncology*, (2010) 28:155 (Suppl), Abst 4508.
- Denis, et al., Phase I and Pharmacokinetic Study of RPR116258A, A Novel Taxane Derivative, Administered Intravenously over 1 hour every 3 weeks, *Clinical Cancer Research*, vol. 6, (2000), (Supplement), Abstract 568, p. 4579s.
- Lortholary, et al., Phase I and Pharmacokinetics (PK) Study of RPR116258A Given as 1-hour Infusion in Patients (pts) With Advanced Solid Tumors, *Clinical Cancer Research*, vol. 6, (2000), (Supplement), Abstract 569, pp. 4579s-4580s.
- Oudard, et al., Cabazitaxel Plus Prednisone/Prednisolone Significantly Increases Overall Survival Compared to Mitoxantrone Plus Prednisone/Prednisolone in Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC) Previously Treated With Docetaxel: Final Results With Updated Overall Survival of a Multinational Phase III Trial (TROPIC), *Ann. of Oncology*, vol. 21, (Suppl. 8), p. viii272, (2010), Abstract 871PD.
- Kris, et al., *Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology*, *J Clin Oncology*, (2010), vol. 28, No. 36, pp. 5327-5347, 947.
- Drug Data Report, Antimitotic Drugs, (2003), vol. 25, No. 6, p. 550, (2003).
- Drug Data Report, Cabazitaxel, (2010), vol. 32, No. 10, pp. 999-1017 at p. 1012.
- Sanofi-Aventis Press Release: Resilient Sales and Business EPS in Q3 2010, (Oct. 28, 2010), pp. 1-24.
- Sanofi-Aventis Press Release: EPS Growth in Q2 2010, (Jul. 29, 2010), pp. 1-27.
- ClinicalTrials.gov, Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment, Web site, (2010), pp. 1-7 [retrieved on Jan. 6, 2014].

(56)

References Cited

OTHER PUBLICATIONS

ClinicalTrials.gov, Effect of Cabazitaxel on the QTc Interval in Cancer Patients (QT-Cab), Web site, (2010) Mar. 24, pp. 1-7 [retrieved on Jan. 6, 2014].

Sanofi-Aventis Press Release: Sanofi-Aventis Delivers Double-Digit EPS Growth in 2009 as the Transformation Program Progresses, (Feb. 10, 2010), pp. 1-26.

ClinicalTrials.gov, A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer, Web Site, (Jul. 22, 2009), pp. 1-7 [retrieved on Jan. 6, 2014].

Sanofi-Aventis Press Release: Sanofi-Aventis Delivers 2008 Results Above Guidance, (2009), Feb. 11, pp. 1-27.

Numata, et al., The Preliminary Results of Docetaxel-Prednisolone Combination Therapy for the Japanese Patients With Hormone-Refractory Prostate Cancer, *Acta Urol. Jpn.*, vol. 53, pp. 93-97, (2007).

Miura, et al., A Case of Hormone-Refractory Prostate Cancer (HRPC) With Tumor Fever Responding to Docetaxel Plus Prednisolone Therapy, *Jpn J Cancer Chemother*, vol. 33, No. 6, pp. 841-844, (2006).

Shimazui, et al., Three-Weekly Docetaxel With Prednisone is Feasible for Japanese Patients With Hormone-Refractory Prostate Cancer: A Retrospective Comparative Study With Weekly Docetaxel Alone, *Jpn J Clin Oncol*, (2007), vol. 37, No. 8, pp. 603-808.

Kola, et al., Can the Pharmaceutical Industry Reduce Attrition Rates?, *Nature Reviews Drug Discovery*, vol. 3, (2004), pp. 711-715.

Dimasi, et al., Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs, *Nature*, vol. 87, No. 3, pp. 272-277, (2010).

Bertold, et al., Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study, *Journal of Clinical Oncology*, vol. 26, No. 2, (2008) pp. 242-245.

Merck Index 14th 2006, No. 190, p. 36, Agomelatine.

Tan, Novel Agents in the Treatment of Hormone-Independent Metastatic Prostate Cancer, *Actas Urol Esp.*, (2007), vol. 31, No. 6, pp. 660-685 (followed by non-verified English translation).

El Docetaxel Asociado a la Prednisona Mejora el Cancer de Prostate, [Retrieved from the internet on Oct. 26, 2012] Retrieved from <http://www.rmedicinageriatrica.com.ar/viewnews.php?id=EEpVVFZVppsBCjOavj>.

Dres, et al., Treatment alternatives for advanced prostate cancer, [Retrieved from the internet on Jul. 29, 2014] Retrieved from <http://www.intramed.net/contenido.asp?contenidoID=37957> (followed by non-verified English translation).

Taxotere (Docetaxel) Mejora Significativamente la Supervivencia de los Pacientes con Cancer de Prostate Avanzado, PMFARMA Espana, (2007).

Docetaxel Reduce el Riesgo de Muerte en Pacientes con Cancer de Prostate Metastatico Androgeno Independiente, [Retrieved from the internet on Jul. 29, 2014]. Retrieved from <http://www.intramed.net/contenido.asp?contenidoID=31823> (followed by non-verified English translation).

Cancer de Prostata Diseminado, Quimioterapia. [Retrieved from the internet on Jul. 29, 2014]. Retrieved from http://www.guiasalud.es/egpc/cancer_prostata/resumida/apartado06/otros02.html, pp. 1-9.

Revision Sistemática y Modelo Económico de Efectividad Clínica y Coste-Efectividad de Docetaxel en Combinación con Prednisona/Prednisolona para el Tratamiento de Cancer de Prostata Metastatico Refractario a Hormonas, [Retrieved from the internet on Jul. 29, 2014]. Retrieved from <http://www.sefh.es/sefnboletin/vernoticiaboletin.php?id=2663>.

Figg et al., Cabazitaxel Filling One of the Gaps in the Treatment of prostate Cancer. *Cancer Biology & Therapy*, vol. 10, No. 12, pp. 1233-1234, (2010).

Mirtsching, Prostate Cancer Clinical Trials in Dallas; Texas Area. [Retrieved from the Internet on Aug. 19, 2014]. Retrieved from <http://www.healthcentral.com/prostate/c/5618/14589/dallas-texas-area>, pp. 3-4.

* cited by examiner




FIG. 1

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.